AGIO vs. ARQT

In the year-to-date period, AGIO achieves a -3.10% return, which is significantly lower than ARQT's -1.87% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AGIO Sharpe Ratio is -0.29, which is lower than the ARQT Sharpe Ratio of 0.83. The chart below compares the historical Sharpe Ratios of AGIO and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither AGIO nor ARQT has paid dividends to shareholders.

The maximum AGIO drawdown since its inception was -87.36%, smaller than the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for AGIO and ARQT.

The current volatility for Agios Pharmaceuticals, Inc. (AGIO) is 12.60%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 15.51%. This indicates that AGIO experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Agios Pharmaceuticals, Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.